News Medical on MSN1h
Addressing COPD and metabolic syndrome requires comprehensive research efforts
Additional research addressing the connection between chronic obstructive pulmonary disease (COPD) and metabolic syndrome is ...
Expanded research on COPD and metabolic syndrome would advance patient-centered care, expert argues
Additional research addressing the connection between chronic obstructive pulmonary disease (COPD) and metabolic syndrome is ...
NOLA.com6d
Chronic lung disease rates increase in Louisiana, despite national rates remaining the same
In 2021,138,825 people died from COPD in the U.S., making it the sixth overall leading cause of death and the fifth ...
News Medical on MSN9h
Smoking before age 15 significantly increases risk of chronic lung disease
A study reveals childhood smoking significantly increases COPD risk in adulthood, highlighting the need for targeted ...
California wildfires: How smoke, poor air quality can impact health of people hundreds of miles from Los Angeles
Smoke from wildfires — like the ones in Los Angeles — can have health consequences. Here's what experts expect.
Verywell Health on MSN1h
Inhaling Wildfire Smoke Can Cause Long-Term Health Risks: How To Limit Your Exposure
While wildfires can cause immediate destruction to homes and towns, a few weeks of smoke exposure should not have long-term ...
Pharmaceutical Technology10d
TRN-157 by Theron Pharmaceuticals for Chronic Obstructive Pulmonary Disease (COPD): Likelihood of Approval
TRN-157 is under clinical development by Theron Pharmaceuticals and currently in Phase I for Chronic Obstructive Pulmonary Disease (COPD).
AerWave Completes First-in-Human Study to Advance Disease-Modifying Ultrasound-Based Therapy for COPD and Asthma
Company has also raised $12 million in funding led by Lucius Partners NEW YORK, Jan. 08, 2025 (GLOBE NEWSWIRE) -- AerWave Medical, a leader in ultrasound-based interventional pulmonary solutions, ...
Pharmaceutical Technology10d
AZD-6793 by AstraZeneca for Chronic Obstructive Pulmonary Disease (COPD): Likelihood of Approval
AZD-6793 is under clinical development by AstraZeneca and currently in Phase I for Chronic Obstructive Pulmonary Disease (COPD).
pulmonologyadvisor1d
COPD: Early Disease May Be Linked to Impaired FEV1/FVC Trajectories, Wheezing
Individuals with early-onset COPD and rapidly progressive pre-COPD frequently have a decades-long history of impaired ...